Stay updated on Nab-Sirolimus+Pazopanib in Nonadipocytic Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus+Pazopanib in Nonadipocytic Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Nab-Sirolimus+Pazopanib in Nonadipocytic Soft Tissue Sarcomas Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed the phrase 'Last Update Posted (Estimated)' and replaced it with 'Last Update Posted'.SummaryDifference0.0%
- Check9 days agoChange DetectedThe study has been terminated due to loss of financial support, and several key metrics related to patient outcomes have been updated with new timelines and definitions, while previous Phase II data has been removed.SummaryDifference4%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new version of the study, including the addition of a new principal investigator and collaborators, while significant details about the study's methodology and inclusion criteria have been removed.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Nab-Sirolimus+Pazopanib in Nonadipocytic Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus+Pazopanib in Nonadipocytic Soft Tissue Sarcomas Clinical Trial page.